You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 8, 2025

Patent: 10,012,654


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,012,654
Title:Biomarkers in inflammatory bowel disease
Abstract: The present invention provides a method of determining whether a patient with inflammatory bowel disease (IBD) and who has been treated with anti TNF.alpha. therapy is in immunological remission (IR), said method comprising determining the level of a cytokine selected from TNF.alpha., IL-17 and IFN-y in a Gl mucosal sample from said patient. Also provided are methods of prognosis and treatment using said method of determination, in particular discontinuing treatment if said patient is in IR and continuing treatment if said patient is not in IR.
Inventor(s): Florholmen; Jon (Tromso, NO), Olsen; Trine (Tromso, NO), Rismo; Renathe (Tromso, NO), Goll; Rasmus (Tromso, NO), Cui; Guanglin (Tromso, NO)
Assignee: UNIVERSITY OF TROMSO (Tromso, NO)
Application Number:14/653,750
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Analyzing the Claims and Patent Landscape of United States Patent 10,012,654

Introduction

When analyzing a patent, it is crucial to delve into the specifics of the claims, the broader patent landscape, and the implications of the patent's existence. This article will provide a comprehensive and critical analysis of the claims and the patent landscape for United States Patent 10,012,654, focusing on key aspects such as claim construction, patentability, and the impact on the relevant industry.

Understanding Patent Claims

What are Patent Claims?

Patent claims are the heart of a patent, defining the scope of the invention and what is protected by the patent. Each claim must be reviewed to determine which elements or subcombinations are embraced by that claim[2].

Claim Construction

For United States Patent 10,012,654, the claims need to be interpreted in light of the total disclosure contained in the patent. This involves analyzing the claimed subject matter to ensure it advances the state of the art in the field of endeavor of the invention. The primary classification of the patent is assigned based on the main inventive concept, and secondary classifications are assigned to additional invention information[2].

Patentability Requirements

Novelty and Non-Obviousness

To be patentable, an invention must meet the requirements of novelty and non-obviousness. This means the invention must be new and not obvious to a person having ordinary skill in the relevant field. The patent must demonstrate that it did not exist before and that it is a significant improvement over existing technologies[3].

Prior Art Considerations

Prior art, as defined under pre-AIA 35 U.S.C. 102(g), includes inventions made by others that have not been abandoned, suppressed, or concealed. For United States Patent 10,012,654, any prior art that could potentially invalidate the patent must be carefully considered. This includes determining whether the invention was conceived and reduced to practice before the filing date of the patent[3].

The Covered Business Method (CBM) Program

Relevance to Business Method Patents

If United States Patent 10,012,654 is a business method patent, it could be subject to the Covered Business Method (CBM) program. The CBM program allows entities facing patent infringement lawsuits to challenge the validity of business method patents by demonstrating that they do not meet the requirements for patentability. This program can provide a faster and more cost-effective alternative to federal court litigation[1].

Patent Landscape Analysis

Industry Trends and Innovations

To understand the patent landscape, it is essential to analyze industry trends and innovations. For example, in the field of hydrogen and fuel cell technologies, there has been a significant increase in patent filings over the years, with private companies leading in the number of patent awards[4].

Competitor Analysis

Identifying competitors and their patent portfolios is crucial. This involves analyzing the types of organizations receiving patent awards, such as private companies, national laboratories, and universities. Understanding the distribution of patents across different subprograms and technologies helps in gauging the competitive landscape[4].

Impact on the Industry

Innovation and R&D

Patents like United States Patent 10,012,654 can drive innovation by providing exclusive rights to inventors, encouraging further research and development. The Hydrogen and Fuel Cell Technologies Office (HFTO) patent tracking and analysis, for instance, highlights the impact of R&D funding on the development of new technologies[4].

Commercialization and Adoption

The commercialization and adoption of patented technologies are key indicators of their impact. Patents that have been commercialized or are in use by organizations signify successful innovation and market acceptance. This can influence industry standards and practices[4].

Stakeholder Views and Program Effectiveness

Feedback from Stakeholders

Stakeholder views on the effectiveness of patent programs, such as the CBM program, are invaluable. Stakeholders often provide insights into the timeliness of trial decisions, the consistency of reviews, and the overall impact of the program on patent litigation[1].

Extension and Reforms

The decision to extend or reform patent programs depends on stakeholder feedback and the program's effectiveness. For the CBM program, stakeholders have discussed whether it should be extended past its sunset date, considering its benefits in reducing the time and cost associated with patent litigation[1].

Case Studies and Examples

Real-World Applications

Analyzing real-world applications of patented technologies helps in understanding their practical impact. For instance, the development of proton exchange membrane fuel cells, tracked by the HFTO, demonstrates how patented innovations can lead to significant technological advancements[4].

Legal Precedents

Legal precedents, such as those related to interference practice under pre-AIA 35 U.S.C. 102(g), can provide guidance on how patent disputes are resolved. These precedents help in interpreting the scope of patent claims and determining prior art issues[3].

Key Takeaways

  • Claim Construction: The claims of a patent must be carefully interpreted to determine the scope of protection.
  • Patentability: The invention must meet novelty and non-obviousness requirements.
  • Industry Trends: Analyzing industry trends and competitor patents is essential for understanding the patent landscape.
  • Impact on Industry: Patents drive innovation and influence industry standards.
  • Stakeholder Feedback: Feedback from stakeholders is crucial for evaluating the effectiveness of patent programs.

FAQs

What is the purpose of the Covered Business Method (CBM) program?

The CBM program allows entities facing patent infringement lawsuits to challenge the validity of business method patents at the USPTO, providing a faster and more cost-effective alternative to federal court litigation.

How are patent claims constructed and interpreted?

Patent claims are interpreted in light of the total disclosure contained in the patent, with the primary classification assigned based on the main inventive concept and secondary classifications for additional invention information.

What are the key requirements for patentability?

To be patentable, an invention must be novel, non-obvious, and advance the state of the art in its field.

How does the patent landscape influence industry innovation?

The patent landscape drives innovation by providing exclusive rights to inventors, encouraging further research and development, and influencing industry standards and practices.

What role do stakeholders play in evaluating patent programs?

Stakeholders provide valuable feedback on the timeliness of trial decisions, the consistency of reviews, and the overall impact of patent programs, which helps in deciding whether to extend or reform these programs.

Sources

  1. GAO Report: Assessment of the Covered Business Method Patent Review Program, GAO-18-320, March 2018.
  2. USPTO Examiners Handbook: Patent Analysis for Placement into System (Claimed Disclosure), Chapter Three, July 2016.
  3. USPTO MPEP: Pre-AIA 35 U.S.C. 102(g), Section 2138, R-01.2024.
  4. DOE Patent Analysis: hfto-2021-patent-analysis.pdf, Pacific Northwest National Laboratory, 2023.

More… ↓

⤷  Subscribe

Details for Patent 10,012,654

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Janssen Biotech, Inc. REMICADE infliximab For Injection 103772 August 24, 1998 ⤷  Subscribe 2032-12-21
Abbvie Inc. HUMIRA adalimumab Injection 125057 December 31, 2002 ⤷  Subscribe 2032-12-21
Abbvie Inc. HUMIRA adalimumab Injection 125057 February 21, 2008 ⤷  Subscribe 2032-12-21
Abbvie Inc. HUMIRA adalimumab Injection 125057 April 24, 2013 ⤷  Subscribe 2032-12-21
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.